Key Points
- Insider selling: Kestra Medical Technologies insider Brian Daniel Webster sold 15,000 shares on May 15 at an average price of $20.96, worth $314,400. He still held 334,786 shares after the sale.
- Recurring sales: Webster has also sold 15,000 shares each on April 15, March 17, and February 17, indicating a pattern of insider selling over recent months.
- Company snapshot: KMTS shares were down 1.2% and the company recently missed EPS estimates, though quarterly revenue rose 62.7% year over year. Analysts currently rate the stock a consensus Hold with an average price target of $27.40.
Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) insider Brian Daniel Webster sold 15,000 shares of the company's stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $20.96, for a total transaction of $314,400.00. Following the sale, the insider owned 334,786 shares of the company's stock, valued at approximately $7,017,114.56. The trade was a 4.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Brian Daniel Webster also recently made the following trade(s):
- On Wednesday, April 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $20.04, for a total transaction of $300,600.00.
- On Tuesday, March 17th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $20.27, for a total transaction of $304,050.00.
- On Tuesday, February 17th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $25.60, for a total value of $384,000.00.
Kestra Medical Technologies Stock Down 1.2%
Shares of NASDAQ:KMTS opened at $19.59 on Tuesday. Kestra Medical Technologies, Ltd. has a 1 year low of $13.25 and a 1 year high of $30.00. The company has a market cap of $1.14 billion, a PE ratio of -4.95 and a beta of 0.82. The company has a debt-to-equity ratio of 0.15, a current ratio of 7.32 and a quick ratio of 7.32. The stock's 50-day moving average is $20.65 and its 200 day moving average is $23.86.
Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last announced its quarterly earnings results on Tuesday, March 17th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.01). Kestra Medical Technologies had a negative net margin of 171.87% and a negative return on equity of 65.49%. The business had revenue of $24.55 million for the quarter. The company's quarterly revenue was up 62.7% on a year-over-year basis. Sell-side analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.34 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of research analysts recently issued reports on KMTS shares. Weiss Ratings restated a "sell (d-)" rating on shares of Kestra Medical Technologies in a report on Monday, March 23rd. BTIG Research restated a "buy" rating and set a $32.00 price target on shares of Kestra Medical Technologies in a report on Tuesday, April 7th. Finally, The Goldman Sachs Group lowered their price objective on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a "neutral" rating for the company in a report on Thursday, April 9th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Kestra Medical Technologies currently has an average rating of "Hold" and a consensus target price of $27.40.
Read Our Latest Report on Kestra Medical Technologies
Institutional Trading of Kestra Medical Technologies
Several institutional investors and hedge funds have recently bought and sold shares of KMTS. Farther Finance Advisors LLC purchased a new stake in Kestra Medical Technologies in the fourth quarter worth about $31,000. Russell Investments Group Ltd. lifted its holdings in shares of Kestra Medical Technologies by 43.5% during the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company's stock valued at $41,000 after purchasing an additional 474 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in shares of Kestra Medical Technologies in the 3rd quarter worth approximately $48,000. BNP Paribas Financial Markets grew its stake in shares of Kestra Medical Technologies by 148.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company's stock worth $65,000 after buying an additional 1,638 shares during the last quarter. Finally, Daiwa Securities Group Inc. purchased a new stake in shares of Kestra Medical Technologies in the 4th quarter worth approximately $72,000.
About Kestra Medical Technologies
(
Get Free Report)
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
